

## AIMS AND SCOPE

Gut publishes high quality original papers on all aspects of gastroenterology and hepatology as well as topical, authoritative editorials, comprehensive reviews, case reports, therapy updates and other articles of interest to gastroenterologists and hepatologists.

## EDITOR

Professor Robin C Spiller

## SPECIAL SECTIONS EDITOR

Ian Forgacs

## ASSOCIATE EDITORS

David H Adams  
John C Atherton  
Ray J Playford  
Jürgen Scholmerich  
Jan Tack  
Alastair J M Watson

## EVIDENCE BASED GASTROENTEROLOGY ADVISORY GROUP

Richard F A Logan  
Stephen J W Evans  
Andrew Hart  
Jane Metcalf

## EDITORIAL OFFICE MANAGER

Claire Castle

## EDITORIAL ASSISTANTS

Alex Hodge  
Sarah Taylor

## TECHNICAL EDITORS

Linda Gough  
Josie Stephenson

## EDITORIAL BOARD

I Bjarnason - UK	M F Neurath - USA
G E Boeckstaens - Netherlands	M Novelli - UK
L Bueno-France	D Schuppan - Germany
A M Di Bisceglie - USA	F Shanahan - Ireland
H J Cooke - USA	N A Shepherd - UK
E El-Omar - UK	R C Spiller - UK
S L Friedman - USA	J J Y Sung - Hong Kong
L Greco - Italy	G Tougas - Canada
R Jones - UK	G Triadafilopoulos - USA
M A Kamm - UK	Z Tulassay - Hungary
E J Kuipers - Netherlands	S J H Van Deventer - Netherlands
G W McCaughan - Australia	S J W Evans (Statistical Adviser)
K E L McColl - UK	Editor, British Medical Journal
H R Mertz - USA	
K Moore - UK	

## LOCAL EDITIONS

China  
Excerpta Medica Asis Ltd  
19/F Eight Commercial Tower  
8 Sun Yip Street  
Chai Wang  
Hong Kong  
Telephone: +852 2965 1300  
Fax: +852 2976 0778

Netherlands/Belgium  
Medicom Exvcel  
Box 151  
1400 AD Bussum  
Netherlands  
Telephone: +31 35 69 52480  
Fax: +31 35 69 48565

## COPYRIGHT

© 2003 BMJ Publishing Group & British Society of Gastroenterology. All rights reserved; no part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without the prior permission of Gut.


Authors are required to grant Gut an exclusive licence to publish  
Print ISSN 0017 5749  
Online ISSN 1468 3288  
Publication: Monthly (subscribers also receive all supplements)

## INSTRUCTIONS TO AUTHORS

Full instructions are available online at [www.gutjnl.com/misc/ifora.shtml](http://www.gutjnl.com/misc/ifora.shtml)  
If you do not have web access please contact the editorial office

Gut is published by BMJ Publishing Group and printed in the UK on acid free paper by Cambrian Printers, Aberystwyth

Periodicals postage paid, Rahway, NJ. Postmaster: send address changes to: Gut, c/o Mercury Airfreight International Ltd, 365 Blair Road, Avenel, NJ 07001, USA



Immunofluorescence staining of jejunal mucosa from a DQ8+ coeliac patient. (From the paper by Mazzarella *et al*, pp 57–62).



See p 24

**NEW  
ONLINE  
SUBMISSION  
GO TO  
WEBSITE  
TO SUBMIT YOUR  
MANUSCRIPT**



[www.publicationethics.org.uk](http://www.publicationethics.org.uk)

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

## Leading article

- 1 Is intestinal metaplasia of the stomach reversible? *M M Walker*

## Commentaries

- 5 s, M, L, XL . . . *T Wang, G Triadafilopoulos*  
7 HLA-DQ8 as an Ir gene in coeliac disease  
*K E A Lundin*  
8 A rat virus visits the clinic: translating basic discoveries into clinical medicine in the 21st century  
*C R Boland, A Goel*

## Clinical @Iert

- 10 Dyspepsia management in the millennium: to test and treat or not? *B C Delaney*

## Science @Iert

- 12 RUNX 3, apoptosis 0: a new gastric tumour suppressor  
*S F Moss*

## Debate

- 14 Protagonist: Ablative mucosectomy is the procedure of choice to prevent Barrett's cancer  
*H Barr*  
16 Antagonist: Ablative mucosectomy is the procedure of choice to prevent Barrett's cancer  
*R C Fitzgerald*

## Oesophageal disease

- 18 Biopsy surveillance is still necessary in patients with Barrett's oesophagus despite new endoscopic imaging techniques  
*K Egger, M Werner, A Meining, R Ott, H-D Allescher, H Höfler, M Classen, T Rösch*  
24 Magnification chromoendoscopy for the detection of intestinal metaplasia and dysplasia in Barrett's oesophagus  
*P Sharma, A P Weston, M Topalovski, R Cherian, A Bhattacharyya, R E Sampliner*  
28 Time gated fluorescence spectroscopy in Barrett's oesophagus  
*M-A E J Ortner, B Ebert, E Hein, K Zumbusch, D Nolte, U Sukowski, J Weber-Eibel, B Fleige, M Dietel, M Stolte, G Oberhuber, R Porschen, B Klump, H Hörtnagl, H Lochs, H Rinneberg*  
34 Endocinch therapy for gastro-oesophageal reflux disease: a one year prospective follow up  
*Z Mahmood, B P McMahon, Q Arfin, P J Byrne, J V Reynolds, E M Murphy, D G Weir*

## Helicobacter pylori

- 40 Treatment of *Helicobacter pylori* in functional dyspepsia resistant to conventional management: a double blind randomised trial with a six month follow up  
*H R Koelz, R Arnold, M Stolte, M Fischer, A L Blum, the FROSCHE Study Group*

## Small intestine

- 47 Avenin fails to induce a Th1 response in coeliac tissue following in vitro culture  
*C Kilmartin, S Lynch, M Abuzakouk, H Wieser, C Feighery*

- 53 Tachykinins potently stimulate human small bowel blood flow: a laser Doppler flowmetry study in humans *P T Schmidt, M Lördal, B Gazelius, P M Hellström*

- C**57 An immunodominant DQ8 restricted gliadin peptide activates small intestinal immune response in in vitro cultured mucosa from HLA-DQ8 positive but not HLA-DQ8 negative coeliac patients *G Mazarella, M Maglio, F Paparo, G Nardone, R Stefanile, L Greco, Y van de Wal, Y Kooy, F Koning, S Auricchio, R Troncone*

**Therapy update**

- 63 Osteoporosis in inflammatory bowel disease *J Compston*

**Inflammatory bowel disease**

- 65 Increased expression of interleukin 17 in inflammatory bowel disease *S Fujino, A Andoh, S Bamba, A Ogawa, K Hata, Y Araki, T Bamba, Y Fujiyama*
- 71 CARD4/NOD1 is not involved in inflammatory bowel disease *H Zouali, S Lesage, F Merlin, J-P Cézard and the EPWG-IBD group, J-F Colombel and the EPIMAD group, J Belaiche and the GETAID group, S Almer, C Tysk, C O'Morain, M Gassull, S Christensen, Y Finkel, R Modigliani, C Gower-Rousseau, J Macry, M Chamaillard, G Thomas, J-P Hugot*
- 75 Association between K469E allele of intercellular adhesion molecule 1 gene and inflammatory bowel disease in a Japanese population *J Matsuzawa, K Sugimura, Y Matsuda, M Takazoe, K Ishizuka, T Mochizuki, S S Seki, O Yoneyama, H Bannnai, K Suzuki, T Honma, H Asakura*
- 79 Induction of experimental ulcerative colitis by *Fusobacterium varium* isolated from colonic mucosa of patients with ulcerative colitis *T Ohkusa, I Okayasu, T Ogihara, K Morita, M Ogawa, N Sato*
- 84 Changes in chemical coding of myenteric neurones in ulcerative colitis *M Neunlist, P Aubert, C Toquet, T Oreshkova, J Barouk, P A Lehur, M Schemann, J P Galmiche*
- 91 Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component? *W M Gonsalkorale, C Perrey, V Pravica, P J Whorwell, I V Hutchinson*

**Cancer**

- 94 Butyrate induced Caco-2 cell apoptosis is mediated via the mitochondrial pathway *F M Ruemmele, S Schwartz, E G Seidman, S Dionne, E Levy, M J Lentze*
- C**101 A prospective study of circulating mutant KRAS2 in the serum of patients with colorectal neoplasia: strong prognostic indicator in postoperative follow up *B M Ryan, F Lefort, R McManus, J Daly, P W N Keeling, D G Weir, D Kelleher*

**Biliary disease**


- 109 Gall bladder dysmotility: a risk factor for gall stone formation in hypertriglyceridaemia and reversal on triglyceride lowering therapy by bezafibrate and fish oil *J J A M Jonkers, A H M Smelt, M Ledebøer, M E Hollum, I Biemond, F Kuipers, F Stellaard, R Boverhof, A E Meinders, C H B W Lamers, A A M Masclee*
- 116 Risk factors for recurrent bile duct stones after endoscopic papillotomy *T Ando, T Tsuyuguchi, T Okugawa, M Saito, T Ishihara, T Yamaguchi, H Saisho*



See p 57

**Liver disease**

- 122 Different hepatitis B virus core gene mutations in children with chronic infection and hepatocellular carcinoma *Y-H Ni, M-H Chang, H-Y Hsu, D-J Tsuei*
- 126 Impact of smoking on histological liver lesions in chronic hepatitis C *C C Hézode, I Lonjon, F Roudot-Thoraval, J-P Mavrier, J-M Pawlotsky, E S Zafrani, D Dhumeaux*
- 130 Acute propranolol administration effectively decreases portal pressure in patients with TIPS dysfunction *L Bellis, E Moitinho, J G Abraldes, M Graupera, J C García-Pagán, J Rodés, J Bosch*
- 134 MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study *F Botta, E Giannini, P Romagnoli, A Fasoli, F Malfatti, B Chiarbonello, E Testa, D Risso, G Colla, R Testa*



See p 65

**Case report**

- 140 Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine *B A Kaskas, E Louis, U Hindorf, E Schaeffeler, J Deflandre, F Graepler, K Schmiegelow, M Gregor, U M Zanger, M Eichelbaum, M Schwab*

**Gut file**



- 143 Elemental diet in the treatment of orofacial Crohn's disease *E A B Cameron, S J Middleton*

**Review**

- 144 Mitogen activated protein (MAP) kinase signal transduction pathways and novel anti-inflammatory targets *D W Hommes, M P Peppelenbosch, S J H van Deventer*

**PostScript**

- 152 Letters
- 156 Book reviews Correction Notices



See p 94